Affiliations 

  • 1 Raghavendra Institute of Pharmaceutical Education and Research, Anantapur, India
  • 2 Department of Pharmacology, Balaji College of Pharmacy, Anantapur, India
  • 3 College of Pharmacy, Riyadh ELM University, Riyadh, Saudi Arabia
  • 4 Faculty of Pharmacy, Dr. M.G.R. Educational and Research Institute, Chennai, India
  • 5 Vaccines and Bioprocessing Centre, King Abdulaziz City for Science and Technology (KACST), Riyadh, Saudi Arabia
  • 6 Department of Pharmaceutics, College of Pharmaceutical Sciences, Dayananda Sagar University, Bengaluru, India
  • 7 Faculty of Pharmaceutical Sciences, UCSI University, Kuala Lumpur, Malaysia
  • 8 School of Pharmacy, ITM University, Gwalior, India
  • 9 Amity Institute of Pharmacy, Amity University, Gwalior, India
  • 10 GITAM School of Pharmacy, GITAM University Hyderabad Campus, Rudraram, India
  • 11 Department of Biotechnology, School of Engineering and Technology, Sharda University, Greater Noida, India
  • 12 Faculty of Biotechnology and Food Sciences, Slovak University of Agriculture in Nitra, Nitra, Slovakia
  • 13 Laboratory of Animal Immunology and Biotechnology, Department of Animal Morphology, Physiology and Genetics, Faculty of AgriSciences, Mendel University in Brno, Brno, Czechia
  • 14 Department of Life Science and Bioinformatics, Assam University, Silchar, India
Front Endocrinol (Lausanne), 2023;14:1201198.
PMID: 37560308 DOI: 10.3389/fendo.2023.1201198

Abstract

Colorectal cancer (CRC) is one of the most deaths causing diseases worldwide. Several risk factors including hormones like insulin and insulin like growth factors (e.g., IGF-1) have been considered responsible for growth and progression of colon cancer. Though there is a huge advancement in the available screening as well as treatment techniques for CRC. There is no significant decrease in the mortality of cancer patients. Moreover, the current treatment approaches for CRC are associated with serious challenges like drug resistance and cancer re-growth. Given the severity of the disease, there is an urgent need for novel therapeutic agents with ideal characteristics. Several pieces of evidence suggested that natural products, specifically medicinal plants, and derived phytochemicals may serve as potential sources for novel drug discovery for various diseases including cancer. On the other hand, cancer cells like colon cancer require a high basal level of reactive oxygen species (ROS) to maintain its own cellular functions. However, excess production of intracellular ROS leads to cancer cell death via disturbing cellular redox homeostasis. Therefore, medicinal plants and derived phytocompounds that can enhance the intracellular ROS and induce apoptotic cell death in cancer cells via modulating various molecular targets including IGF-1 could be potential therapeutic agents. Alkaloids form a major class of such phytoconstituents that can play a key role in cancer prevention. Moreover, several preclinical and clinical studies have also evidenced that these compounds show potent anti-colon cancer effects and exhibit negligible toxicity towards the normal cells. Hence, the present evidence-based study aimed to provide an update on various alkaloids that have been reported to induce ROS-mediated apoptosis in colon cancer cells via targeting various cellular components including hormones and growth factors, which play a role in metastasis, angiogenesis, proliferation, and invasion. This study also provides an individual account on each such alkaloid that underwent clinical trials either alone or in combination with other clinical drugs. In addition, various classes of phytochemicals that induce ROS-mediated cell death in different kinds of cancers including colon cancer are discussed.

* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.